Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis

NCT07121413 is registered in ClinicalTrials.gov with Shanghai Synvida Biotechnology Co.,Ltd. as lead sponsor.

NCT NCT07121413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07121413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
Lead sponsor
Shanghai Synvida Biotechnology Co.,Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
November 4, 2025
Completion date
December 31, 2026
Enrollment
48 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis(ipf)